Introduction — This topic includes links to society and government-sponsored guidelines from selected countries and regions around the world. We will update these links periodically; newer versions of some guidelines may be available on each society's website. Some societies may require users to log in to access their guidelines.
The recommendations in the following guidelines may vary from those that appear in UpToDate topic reviews. Readers who are looking for UpToDate topic reviews should use the UpToDate search box to find the relevant content.
Links to related guidelines are provided separately. (See "Society guideline links: Hypertension in children" and "Society guideline links: Diabetes mellitus in adults" and "Society guideline links: Fibromuscular dysplasia".)
International
●World Health Organization (WHO): Guideline for the pharmacological treatment of hypertension in adults (2021)
●International Society of Hypertension (ISH): Global hypertension practice guidelines (2020)
Canada
●Choosing Wisely Canada: Don't prescribe angiotensin converting enzyme (ACE) inhibitors in combination with angiotensin II receptor blockers (ARBs) for the treatment of hypertension, diabetic nephropathy and heart failure (2021)
●Choosing Wisely Canada: Don't prescribe nonsteroidal anti-inflammatory drugs (NSAIDS) in individuals with hypertension or heart failure or CKD of all causes, including diabetes (2021)
●Hypertension Canada: Comprehensive guidelines for the prevention, diagnosis, risk assessment, and treatment of hypertension in adults and children (2020)
●Diabetes Canada: Clinical practice guidelines for the treatment of hypertension (2018)
United States
●American Diabetes Association (ADA): Standards of care in diabetes (2023)
•Cardiovascular disease and risk management
●US Preventive Services Task Force (USPSTF): Final recommendation statement on hypertension in adults – Screening (2021)
●US Department of Veterans Affairs (VA)/Department of Defense (DoD): Clinical practice guidelines for the diagnosis and management of hypertension (HTN) in primary care (2020)
●American College of Cardiology (ACC)/American Heart Association (AHA): Guideline on the primary prevention of cardiovascular disease (2019)
●AHA: Scientific statement on the measurement of blood pressure in humans (2019)
●AHA: Scientific statement on resistant hypertension – Detection, evaluation, and management (2018)
●ACC/AHA/American Academy of Physician Assistants (AAPA)/Association of Black Cardiologists (ABC)/American College of Preventive Medicine (ACPM)/American Geriatrics Society (AGS)/American Pharmacists Association (APhA)/American Society of Hypertension (ASH)/American Society for Preventive Cardiology (ASPC)/National Medical Association (NMA)/Preventive Cardiovascular Nurses Association (PCNA): Guideline for the prevention, detection, evaluation, and management of high blood pressure in adults (2017)
●American College of Physicians (ACP) and American Academy of Family Physicians (AAFP): Clinical practice guideline on the pharmacologic treatment of hypertension in adults aged 60 years or older to higher versus lower blood pressure targets (2017)
●American College of Radiology (ACR): ACR Appropriateness Criteria on renovascular hypertension (2017)
●AHA: A scientific statement on the impact of hypertension on cognitive function (2016)
Europe
●European Society of Hypertension (ESH): Practice guidelines for office and out-of-office blood pressure measurement (2021)
●ESH: Position document on nutraceuticals and blood pressure control (2020)
●European Society of Cardiology (ESC)/ESH: Clinical practice guidelines for the management of arterial hypertension (2018)
●ESH: Practice guidelines for ambulatory blood pressure monitoring (2014)
●ESH: Practice guidelines for home blood pressure monitoring (2010)
United Kingdom
●National Institute for Health and Care Excellence (NICE): Interventional procedures guidance on percutaneous transluminal renal sympathetic denervation for resistant hypertension (2023)
●British and Irish Hypertension Society (BIHS): Position document on the management of hypertensive crisis (2022)
●NICE: Guideline on hypertension in adults – Diagnosis and management (2019, updated 2022)
●NICE: Interventional procedures guidance on implanting a baroreceptor stimulation device for resistant hypertension (2015)
●NICE: Quality standard on hypertension in adults (2013, updated 2015)
India
●Indian guidelines on hypertension-IV (2019)
Australia–New Zealand
●National Heart Foundation of Australia: Guideline for the diagnosis and management of hypertension in adults (2016)
●Choosing Wisely Australia: Don't commence therapy for hypertension or hyperlipidaemia without first assessing the absolute risk of a cardiovascular event (2015)
●National Vascular Disease Prevention Alliance (NVDPA): Guidelines for the management of absolute cardiovascular disease risk (2012)
Japan
●[In English] Japanese Society of Hypertension (JSH): Guidelines for the management of hypertension (2019)
●[In Japanese] JSH: Guidelines for hypertension treatment (2019)
